Phase III REACH-2 trial reported in The Lancet Oncology

Hallwang Clinic on Facebook - The phase III REACH-2 trial reported

The phase III REACH-2 trial reported in The Lancet Oncology showed that ramucirumab improved overall and progression-free survival vs placebo in patients with advanced hepatocellular carcinoma and increased alfa-fetoprotein levels.

 

Read more here: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30937-9/fulltext

Leave a Reply

Your email address will not be published. Required fields are marked *